查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球平坦部扁平炎治疗市场 -2023-2030
市场调查报告书
商品编码
1374778

全球平坦部扁平炎治疗市场 -2023-2030

Global Pars Planitis Treatment Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

多年来，全球扁平部炎治疗市场经历了显着的成长和转变，影响其动态的因素有很多。称为平坦部炎的持续性中间葡萄膜炎与任何全身性疾病或感染无关。儘管扁平部炎患者很少出现症状，但他们可能会提到飞蚊症或视力受损。通常没有疼痛或畏光。

政府的投资和研究，特别是在发展中经济体，将继续推动皮质类固醇或免疫抑制剂等新药的使用，并推动全球扁平部扁平炎治疗市场的发展。几位研究人员正在开发相应的创新疗法，目前正在试验中。

市场动态：驱动因素与限制因素

不断成长的融资和收购

在高投资、收入水准和基础设施发展的推动下，已开发经济体的医疗保健产业不断改善。由于研究不断增加，一些国家对扁平部扁平炎治疗的需求很大。不同国家之间的各种合作、收购和技术进步的产品发布将是推动市场成长的关键因素。

2023年7月3日，Viatris的全球生物相似药业务最近被Biocon Biologics收购，该公司还在美国、欧洲和其他100多个国家获得了许多生物相似药许可证。由于收购了 Viatris 的生物相似药业务，Biocon Biologics 现在可以帮助为患者和医疗专业人员提供额外的方便且廉价的治疗替代方案。

在欧洲使用五年和在加拿大使用两年后，Biocon Ltd 旗下子公司Biocon Biologics Ltd (BBL) 宣布HULIO (adalimumab-fkjp) 注射剂，一种修美乐(adalimumab) 的生物仿製药，已可供以下国家的患者使用：美国。

此外，出于多种开发目的，越来越多地利用高水平研究的新技术。扁平部扁平炎病例的增加和创新治疗开发研究的增加将是推动扁平部扁平炎治疗市场成长的主要因素。

与扁平部炎治疗药物相关的副作用

无论采取何种治疗方法，患有平坦部炎的患者患多发性硬化症的可能性都更大，且抗 TNF 药物可能导致脱髓鞘。因此，在对扁平部炎患者使用抗 TNF 药物之前，应格外谨慎并评估风险效益比。

扁平部炎也可以用干扰素成功治疗，但副作用可能包括忧郁或自杀念头。白内障和青光眼是最常使用的类固醇的副作用。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 药物片段
  • 依给药途径分類的片段
  • 按配销通路分類的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 不断成长的融资和收购
      • 不断进步的技术进步与发展
    • 限制
      • 与扁平部炎药物相关的副作用
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • SWOT分析
  • 专利分析
  • 俄乌战争影响分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第7章：透过药物

  • 皮质类固醇
    • 泼尼松（Deltasone、Meticorten、Orasone）
    • 曲安西龙（Amcort）
    • 泼尼松龙 1% (Pred Forte)
  • 免疫抑制剂
    • 甲胺蝶呤（Folex PFS、Rheumatrex）
    • 霉酚酸酯（CellCept、MMF、Myfortic）
    • 环孢素（Sandimmune、Neoral）
    • 硫唑嘌呤（Imuran）
  • 组织胺 H2 受体拮抗剂
    • 西咪替丁（泰胃美）
    • 雷尼替丁（Zantac）
  • 胃泵抑制剂
    • 奥美拉唑（Prilosec）
    • 兰索拉唑（Prevacid）
    • 埃索美拉唑镁（Nexium）
  • 肿瘤坏死因子 (TNF) 抑制剂 (DMARD)
    • 阿达木单抗（阿达木单抗-atto、Amjevita、Humira）

第 8 章：依给药途径分类

  • 口服
  • 静脉
  • 其他的

第 9 章：按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Teva Pharmaceutical Industries Ltd.
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • AbbVie Inc. (Allergan)
  • Aurobindo Pharma USA
  • Pfizer Inc.
  • Genentech, Inc.
  • Novartis AG
  • Rosemont Pharmaceuticals Limited
  • Xiromed
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim Pharmaceuticals, Inc.

第 13 章：附录

简介目录
Product Code: PH7183

Overview

The global pars planitis treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. A persistent intermediate uveitis called pars planitis has not been connected with any systemic illness or infection. Although pars planitis patients rarely experience symptoms, they could mention floaters or impaired vision. There is typically no pain or photophobia.

Government investments and research, particularly in developing economies, will continue to drive utilization of novel medicines like corticosteroids or immunosuppressives and boost the global pars planitis treatment market. The respective innovative treatment are being developed by several researchers and currently are under trials.

Market Dynamics: Drivers & Restraints

Growing funding and acquisitions

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for pars planitis treatment owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On July 3, 2023, the global biosimilars business of Viatris was recently acquired by Biocon Biologics, which has also obtained numerous biosimilar licenses in the United States, Europe, and more than 100 other nations. Biocon Biologics can now assist in supplying patients and medical professionals with additional accessible and inexpensive treatment alternatives thanks to the acquisition of Viatris' biosimilars business.

After five years of use in Europe and two years in Canada, Biocon Biologics Ltd (BBL), a division of Biocon Ltd, announced that HULIO (adalimumab-fkjp) injectable, a biosimilar to Humira (adalimumab), has become accessible to patients in the United States.

Furthermore, the rising utilization of novel technology with high level of research for the several development purposes. Rising pars planitis cases and increasing research for innovative treatment development will be a major factor driving the growth of the pars planitis treatment market.

Side effects associated with the pars planitis treatment drugs

Regardless of treatment, patients with pars planitis could be at a greater likelihood for getting multiple sclerosis and anti-TNF Drugs may predispose to demyelination. Therefore, utmost caution should be utilized and the risk-benefit ratio should be assessed before administering an anti-TNF drug to a patient with pars planitis.

Pars planitis has also been successfully treated with interferon, however side effects can include depression or suicidal thoughts. Cataracts and glaucoma are the side effects of steroids that are most frequently administered.

Segment Analysis

The global pars planitis treatment market is segmented based on drugs, route of administration, distribution channel and region.

Corticosteroids segment accounted for approximately 37% of market share

Prednisolone sodium phosphate or acetate topical treatment, both of which are 1%. Along with oral prednisone, periocular injections with corticosteroids are also beneficial. Treatment options include intravitreal injections of triamcinolone acetonide.

Steroid medications can be used to treat the majority of intermediate uveitis cases. Prednisolone is a medication that is frequently used. Steroids act by interfering with the immune system's regular operation so that it no longer secretes the substances that cause inflammation.

On November 17, 2021, the U.S. Food and Drug Administration has given final approval to Aurobindo Pharma Limited's Abbreviated New Drug Application for Prednisone Tablets USP, 1mg. Prednisone Tablets USP, 1mg from Aurobindo Pharma are a reference-listed drug (RLD) identical to Meticorten Tablets from Schering Corp Sub Schering Plough Corp.

Geographical Penetration

North America accounted for around 36% of market share in 2022

Due to the rising need for pars planitis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for pars planitis treatment.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different classes of drug, and increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of pars planitis treatment market share of this region. The market in this area is growing as people become more aware of various novel approved medicines. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global pars planitis treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for pars planitis treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating pars planitis treatment demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global pars planitis treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various medicines, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and pharmaceutical industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for pars planitis treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global pars planitis treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for inovative treatment.

Key Developments

  • On March 21, 2023, the US Food and Drug Administration (FDA) has approved a high-concentration formulation (HCF) which is citrate-free of Sandoz's biosimilar Hyrimoz (adalimumab-adaz) injection, according to the company, a leader in generic drugs and biosimilars. The reference drug Humira* (adalimumab) covers seven indications, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, and plaque psoriasis. The adalimumab citrate-free HCF (100 mg/mL) is approved to treat these conditions.
  • On March 25, 2021, Omeprazole Prolonged Release Capsules, 20mg, a generic version of Prilosec, have been launched, according to Xiromed LLC, the generic branch of Insud Pharmaceuticals based in New Jersey. Proton pump inhibitors like Prilosec are prescribed for treating gastroesophageal reflux disease (GERD) in both adults and children as well as for treating duodenal and gastric ulcers in adults and maintaining the healing of erosive esophagitis.

Competitive Landscape

The major global players in the market include: Teva Pharmaceutical Industries Ltd., AbbVie Inc. (Allergan), Aurobindo Pharma USA, Pfizer Inc., Genentech, Inc., Novartis AG, Rosemont Pharmaceuticals Limited, Xiromed, Takeda Pharmaceutical Company Limited and Boehringer Ingelheim Pharmaceuticals, Inc. among others.

Why Purchase the Report?

  • To visualize the global pars planitis treatment market segmentation based on drugs, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of pars planitis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global pars planitis treatment market report would provide approximately 61 tables, 59 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drugs
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing funding and acquisitions
      • 4.1.1.2. Rising technological advancements and developments
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with the pars planitis drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. SWOT Analysis
  • 5.6. Patent Analysis
  • 5.7. Russia-Ukraine War Impact Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drugs

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 7.1.2. Market Attractiveness Index, By Drugs
  • 7.2. Corticosteroids*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Prednisone (Deltasone, Meticorten, Orasone)
    • 7.2.4. Triamcinolone (Amcort)
    • 7.2.5. Prednisolone 1% (Pred Forte)
  • 7.3. Immunosuppressives
    • 7.3.1. Methotrexate (Folex PFS, Rheumatrex)
    • 7.3.2. Mycophenolate (CellCept, MMF, Myfortic)
    • 7.3.3. Cyclosporine (Sandimmune, Neoral)
    • 7.3.4. Azathioprine (Imuran)
  • 7.4. Histamine H2-Receptor Antagonist
    • 7.4.1. Cimetidine (Tagamet)
    • 7.4.2. Ranitidine (Zantac)
  • 7.5. Gastric Pump Inhibitors
    • 7.5.1. Omeprazole (Prilosec)
    • 7.5.2. Lansoprazole (Prevacid)
    • 7.5.3. Esomeprazole magnesium (Nexium)
  • 7.6. Tumor Necrosis Factor (TNF) inhibitors (DMARDs)
    • 7.6.1. Adalimumab (Adalimumab-atto, Amjevita, Humira)

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Intravenous
  • 8.4. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Teva Pharmaceutical Industries Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. AbbVie Inc. (Allergan)
  • 12.3. Aurobindo Pharma USA
  • 12.4. Pfizer Inc.
  • 12.5. Genentech, Inc.
  • 12.6. Novartis AG
  • 12.7. Rosemont Pharmaceuticals Limited
  • 12.8. Xiromed
  • 12.9. Takeda Pharmaceutical Company Limited
  • 12.10. Boehringer Ingelheim Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us